ClinicalTrials.gg

Program

debamestrocel

Also written as “Debamestrocel - MSC-NTF (NurOwn)”, “Nurown MSC-NTF cells” and “NurOwn® (MSC-NTF cells)”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Multiple Sclerosis, Chronic Progressive, led by Brainstorm-Cell Therapeutics.

Furthest: phase 3, since Aug 29, 20174 company-led studies, 1 open or runningNext primary completion: Nov 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Brainstorm-Cell Therapeutics41 open or runningphase 3since Aug 29, 2017Dec 17, 2013Nov 1, 2028phase 3 · NCT06973629

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2013First study: phase 2 study in Amyotrophic Lateral SclerosisFirst studyNCT02017912 · 48 enrolled · United States
  2. Aug 29, 2017Phase 3 study in Amyotrophic Lateral SclerosisNCT03280056 · 196 enrolled · United States
  3. Jan 7, 2019Phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT03799718 · 23 enrolled · United States
  4. May 5, 2025Phase 3 study in Amyotrophic Lateral SclerosisNCT06973629 · 200 planned · United States

Ahead

  1. Nov 1, 2028Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT06973629

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06973629Amyotrophic Lateral Sclerosis · United States3Not yet recruitingNov 1, 2028200
NCT03799718Multiple Sclerosis, Chronic Progressive · United States2CompletedMar 11, 202123
NCT03280056Amyotrophic Lateral Sclerosis · United States3CompletedSep 29, 2020196
NCT02017912Amyotrophic Lateral Sclerosis · United States2CompletedMar 201648

How it is read

Names in the registry

  • “Debamestrocel - MSC-NTF (NurOwn)”, 1 entry
  • “Nurown MSC-NTF cells”, 1 entry
  • “NurOwn® (MSC-NTF cells)”, 1 entry
  • “NurOwn (MSC-NTF cells)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
debamestrocel (Brainstorm-Cell Therapeutics): development program | ClinicalTrials.gg